Details for Patent: 11,369,567
✉ Email this page to a colleague
Which drugs does patent 11,369,567 protect, and when does it expire?
Patent 11,369,567 protects ATORVALIQ and is included in one NDA.
This patent has two patent family members in two countries.
Summary for Patent: 11,369,567
| Title: | Aqueous suspension suitable for oral administration |
| Abstract: | The present invention provides liquid oral dosage form of lipid lowering agent suitable for oral administration to human or animals. |
| Inventor(s): | Sandip P. Mehta, Henil Alpeshbhai PATEL, Jayanta Kumar Mandal |
| Assignee: | Liqmeds Worldwide Ltd , FTF Pharma Pvt Ltd |
| Application Number: | US16/308,731 |
|
Patent Claim Types: see list of patent claims | Compound; Dosage form; |
Drugs Protected by US Patent 11,369,567
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cmp Dev Llc | ATORVALIQ | atorvastatin calcium | SUSPENSION;ORAL | 213260-001 | Feb 1, 2023 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 11,369,567
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| European Patent Office | 3468606 | ⤷ Start Trial | |||
| World Intellectual Property Organization (WIPO) | 2017212409 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
